ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BPTH Bio Path Holdings Inc

2.18
0.18 (9.00%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bio Path Holdings Inc NASDAQ:BPTH NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.18 9.00% 2.18 2.18 2.55 2.64 2.10 2.26 5,048,178 05:00:10

Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023

08/11/2023 12:00pm

GlobeNewswire Inc.


Bio Path (NASDAQ:BPTH)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Bio Path Charts.

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview.

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors . The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com. 

Contact Information:                        Investors

Will O’ConnorStern Investor Relations 212-362-1200will@sternir.com  

Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369

 

1 Year Bio Path Chart

1 Year Bio Path Chart

1 Month Bio Path Chart

1 Month Bio Path Chart

Your Recent History

Delayed Upgrade Clock